Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
ARCH Venture Fund IX, L.P. - 31 Dec 2024 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL)
- Filing manager
- ARCH Venture Fund IX, L.P.
- Reporting owner
- Robert Nelsen
- Beneficially owned shares
- 36,597,716 shares
- Large-stake signal
-
Ownership
13%Beneficial ownership of this reported class.
Shares
36,597,716 sharesShares beneficially owned as disclosed.
Event date
31 Dec 2024Date tied to the ownership event or amendment.
Accepted by SEC
14 Feb 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 13%
- Symbol
- LYEL
- Shares outstanding
- 279,371,878 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 14 Feb 2025, 16:55:23 UTC
- Event date
- 31 Dec 2024
- Next SEC filing
- 15 May 2026
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
ARCH Venture Fund IX, L.P. disclosed 13% ownership in Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL) on 31 Dec 2024.
Key facts
- ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL).
- Disclosed ownership: 13%.
- Date of event: 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:55.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (8)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, L.P. | its General Partner | |
| ARCH Venture Fund IX Overage, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX Overage, L.P. | its General Partner | |
| ARCH Venture Partners IX, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX Overage, L.P. | 13% | 36,412,716 | 0 | 36,412,716 | ARCH Venture Partners IX, LLC | its General Partner | |
| ARCH Venture Partners IX, LLC | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director | |
| Keith Crandell | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Keith Crandell | |
| Clinton Bybee | 13% | 36,412,716 | 0 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee | |
| Robert Nelsen | 13% | 36,597,716 | 185,000 | 36,412,716 | /s/ Mark McDonnell | * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen |
CIK / CUSIP context first